274 related articles for article (PubMed ID: 32336167)
21. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
22. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
23. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
24. Precision Medicine Requires Precision Laboratories.
Rajeevan MS; Li T; Unger ER
J Mol Diagn; 2017 Mar; 19(2):226-229. PubMed ID: 28130021
[TBL] [Abstract][Full Text] [Related]
25. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
26. Precision medicine: what's all the fuss about?
Barker R
Scand J Clin Lab Invest Suppl; 2016; 245():S2-5. PubMed ID: 27542001
[TBL] [Abstract][Full Text] [Related]
27. Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics.
Glorikian H; Warburg RJ; Moore K; Malinowski J
Expert Opin Ther Pat; 2018 Feb; 28(2):123-128. PubMed ID: 29224409
[TBL] [Abstract][Full Text] [Related]
28. CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
Wise J; Furness M; McWilliams S; Patton S
Drug Discov Today; 2019 Nov; 24(11):2120-2125. PubMed ID: 31306783
[TBL] [Abstract][Full Text] [Related]
29. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients.
van Waalwijk van Doorn-Khosrovani SB; Pisters-van Roy A; van Saase L; van der Graaff M; Gijzen J; Sleijfer S; Hoes LR; van Berge Henegouwen JM; van der Wijngaart H; van der Velden DL; van Werkhoven E; Retel VP; van Harten WH; Huitema ADR; Timmers L; Gelderblom H; Verheul HMW; Voest EE
Ann Oncol; 2019 May; 30(5):663-665. PubMed ID: 31038154
[No Abstract] [Full Text] [Related]
30. Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.
Scheerens H; Malong A; Bassett K; Boyd Z; Gupta V; Harris J; Mesick C; Simnett S; Stevens H; Gilbert H; Risser P; Kalamegham R; Jordan J; Engel J; Chen S; Essioux L; Williams JA
Clin Transl Sci; 2017 Mar; 10(2):84-92. PubMed ID: 28121072
[TBL] [Abstract][Full Text] [Related]
31. Next-generation companion diagnostics: promises, challenges, and solutions.
Khoury JD; Catenacci DV
Arch Pathol Lab Med; 2015 Jan; 139(1):11-3. PubMed ID: 25166874
[No Abstract] [Full Text] [Related]
32. The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care into an Affordable Reality in Europe.
Wurcel V; Perche O; Lesteven D; Williams DA; Schäfer B; Hopley C; Jungwirth R; Postulka A; Pasmans R; Hermansson LL; Ott M; Glorioso V
Public Health Genomics; 2016; 19(3):137-43. PubMed ID: 27237134
[TBL] [Abstract][Full Text] [Related]
33. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
34. Companion diagnostics: the key to personalized medicine. Foreword.
Jørgensen JT
Expert Rev Mol Diagn; 2015 Feb; 15(2):153-6. PubMed ID: 25597758
[TBL] [Abstract][Full Text] [Related]
35. Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers.
Schroader B; Kong S; Anderson S; Williamson T; Sireci A; Shields K
Expert Rev Anticancer Ther; 2019 Nov; 19(11):929-938. PubMed ID: 31622558
[No Abstract] [Full Text] [Related]
36. [Molecular-Genetic Diagnosis and Molecular-Targeted Therapy in Cancer: Challenges in the Era of Precision Medicine].
Miyachi H
Rinsho Byori; 2015 Oct; 63(10):1188-93. PubMed ID: 26897855
[TBL] [Abstract][Full Text] [Related]
37. The value proposition of molecular medicine.
Waldman SA; Terzic A
Clin Transl Sci; 2012 Feb; 5(1):108-10. PubMed ID: 22376267
[No Abstract] [Full Text] [Related]
38. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
39. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
Farwell MD; Clark AS; Mankoff DA
JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
[No Abstract] [Full Text] [Related]
40. Drug sensitivity testing platforms for gastric cancer diagnostics.
Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]